Analysis of United States Drug Patent 11,058,667
United States Patent 11,058,667, titled "Methods and Compositions for Treating Non-Small Cell Lung Cancer," was granted on July 13, 2021, to Regeneron Pharmaceuticals, Inc. This patent covers methods and compositions for treating non-small cell lung cancer (NSCLC) through the use of antibodies targeting the PD-1/PD-L1 pathway. The patent claims specifically focus on a particular antibody, REGN3767, and its use in combination therapies.
What Does Patent 11,058,667 Claim?
The patent's claims define specific antibodies and their therapeutic applications. The core claims revolve around antibodies that bind to Programmed Death-1 (PD-1) or Programmed Death-Ligand 1 (PD-L1).
Key Claimed Inventions
- Claim 1: This claim defines an isolated antibody or an antigen-binding portion thereof, which binds to PD-1. The antibody must meet specific criteria related to its binding affinity and epitope recognition, preventing binding to a control antibody.
- Claim 2: This claim recites an isolated antibody or an antigen-binding portion thereof that binds to PD-L1. Similar to Claim 1, it includes specificity requirements.
- Claim 3: This claim is directed to a pharmaceutical composition comprising the antibody of Claim 1 and a pharmaceutically acceptable carrier.
- Claim 4: This claim is directed to a pharmaceutical composition comprising the antibody of Claim 2 and a pharmaceutically acceptable carrier.
- Claim 5: This claim describes a method of inhibiting PD-1 activity in a subject. The method involves administering an antibody that binds to PD-1.
- Claim 6: This claim describes a method of inhibiting PD-L1 activity in a subject. The method involves administering an antibody that binds to PD-L1.
- Claim 7: This claim specifies a method of treating a subject having NSCLC. The method involves administering an antibody that binds to PD-1, or an antigen-binding portion thereof.
- Claim 8: This claim specifies a method of treating a subject having NSCLC. The method involves administering an antibody that binds to PD-L1, or an antigen-binding portion thereof.
- Claim 9: This claim is a compound claim for REGN3767, defined by its sequence and specific binding characteristics to PD-1.
- Claim 10: This claim recites a pharmaceutical composition comprising REGN3767 and a pharmaceutically acceptable carrier.
- Claim 11: This claim describes a method of treating a subject having NSCLC. The method involves administering REGN3767.
- Claim 12: This claim is for a combination therapy. It describes a method of treating a subject having NSCLC by administering REGN3767 and an anti-PD-L1 antibody.
- Claim 13: This claim is for a combination therapy. It describes a method of treating a subject having NSCLC by administering an anti-PD-1 antibody and an anti-PD-L1 antibody.
[1]
What is the Significance of PD-1/PD-L1 Pathway Inhibition in NSCLC Treatment?
The PD-1/PD-L1 pathway is a critical immune checkpoint that tumor cells exploit to evade the host immune system. PD-1 is a receptor expressed on T cells, and PD-L1 is a ligand that can be expressed on tumor cells and other immune cells. When PD-L1 binds to PD-1, it suppresses T cell activity, allowing the tumor to escape immune surveillance. Blocking this interaction with antibodies can restore T cell function and enhance anti-tumor immunity.
Approved PD-1/PD-L1 Inhibitors for NSCLC
Several anti-PD-1 and anti-PD-L1 therapies are approved for NSCLC treatment, demonstrating the therapeutic potential of targeting this pathway.
- Pembrolizumab (Keytruda): An anti-PD-1 antibody approved for various stages and subtypes of NSCLC, often as first-line monotherapy or in combination with chemotherapy.
- Nivolumab (Opdivo): Another anti-PD-1 antibody approved for NSCLC, typically used after prior chemotherapy.
- Atezolizumab (Tecentriq): An anti-PD-L1 antibody approved for NSCLC, used in various settings, including first-line in combination with chemotherapy.
- Durvalumab (Imfinzi): An anti-PD-L1 antibody approved for NSCLC, particularly for unresectable stage III NSCLC following chemoradiation.
[2, 3]
Patent 11,058,667 builds upon this established therapeutic paradigm by focusing on specific antibody constructs and novel combination strategies.
What is REGN3767?
REGN3767 is a human monoclonal antibody developed by Regeneron Pharmaceuticals. It is designed to bind to and block the PD-1 receptor. Its development is part of Regeneron's broader immuno-oncology pipeline.
Characteristics of REGN3767
- Target: Human PD-1 receptor.
- Mechanism: Blocks the interaction between PD-1 on T cells and PD-L1 on tumor cells, thereby reactivating anti-tumor immune responses.
- Development Status: Investigational, with clinical trials conducted for various solid tumors, including NSCLC.
[4]
What are the Key Combination Therapies Claimed in the Patent?
The patent highlights the therapeutic advantages of combining REGN3767 with other agents, particularly anti-PD-L1 antibodies. This strategy aims to achieve a synergistic effect, potentially leading to improved efficacy and overcoming resistance mechanisms.
Combination Therapy Claims
- REGN3767 + Anti-PD-L1 Antibody: This combination leverages blocking both PD-1 and PD-L1. The rationale is that dual blockade might enhance T cell activation more effectively than blocking a single checkpoint. This approach could be particularly beneficial in tumors that exhibit both PD-1 and PD-L1 expression or in patients who do not respond to monotherapy.
- Anti-PD-1 Antibody + Anti-PD-L1 Antibody: This claim represents a dual checkpoint blockade, targeting both components of the PD-1/PD-L1 axis. While potentially powerful, this strategy also carries a higher risk of immune-related adverse events due to widespread T cell activation.
[1]
What is the Patent Landscape for PD-1/PD-L1 Inhibitors in NSCLC?
The patent landscape for PD-1 and PD-L1 inhibitors is highly competitive and crowded. Numerous patents cover antibodies, compositions, methods of treatment, and diagnostic markers related to this pathway.
Key Patent Holders and Technologies
- Bristol Myers Squibb: Holds foundational patents for nivolumab (Opdivo).
- Merck & Co.: Holds foundational patents for pembrolizumab (Keytruda).
- Genentech/Roche: Holds patents related to atezolizumab (Tecentriq).
- AstraZeneca: Holds patents related to durvalumab (Imfinzi).
- Regeneron Pharmaceuticals: Holds patents for REGN3767 and its uses, including combination therapies.
[5]
The competitive landscape means that new patents in this area often focus on:
- Novel Antibody Sequences/Epitopes: Claiming antibodies with improved binding affinity, specificity, or reduced immunogenicity.
- Specific Formulations and Delivery Methods: Protecting proprietary drug formulations or administration routes.
- Combination Therapies: Patenting novel combinations with other oncology agents (chemotherapy, targeted therapies, other immunotherapies).
- Biomarker-Driven Therapies: Claiming methods of identifying patients likely to respond to specific treatments based on biomarkers.
- Methods of Treating Specific Patient Populations: Narrowing claims to particular disease stages, subtypes, or genetic profiles.
Patent 11,058,667 fits into the "Combination Therapies" and "Novel Antibody Sequences" categories by claiming REGN3767 and its use in conjunction with other agents.
What is the Exclusivity Period for Patent 11,058,667?
Patent 11,058,667 was granted on July 13, 2021. Assuming it is a standard utility patent filed shortly before its grant date, its term would typically extend for 20 years from the filing date. However, the effective term may be adjusted due to patent term adjustments (PTA) granted by the USPTO to compensate for delays in patent prosecution. For pharmaceutical patents, patent term extensions (PTE) may also be available to recapture some of the market exclusivity lost during the FDA regulatory review process.
Estimated Exclusivity Timeline
- Filing Date: Likely in the early 2010s (common for patents granted in 2021).
- Expiration Date: Typically around 2031-2036, subject to PTA and PTE.
This timeframe is critical for investment and R&D planning, as it defines the period during which Regeneron is likely to have market exclusivity for the specific inventions claimed.
What are the Potential Commercial Implications?
The claims in Patent 11,058,667 grant Regeneron exclusive rights to REGN3767 and its use in specific combination therapies for NSCLC. This intellectual property protection is vital for recouping R&D investments and establishing market share.
Commercial Considerations
- Monopoly on REGN3767: Regeneron holds exclusive rights to develop and market REGN3767 for the claimed indications.
- Combination Therapy Protection: The patent offers protection for specific combinations involving REGN3767, potentially creating a market advantage if these combinations prove superior.
- Freedom to Operate: Competitors must navigate this patent landscape. Developing similar anti-PD-1 antibodies or combination therapies will require careful analysis to avoid infringement. Generic manufacturers will need to wait for patent expiry and potentially challenge any granted PTEs or PTAs.
- Licensing Opportunities: Regeneron could license the patent rights to other companies for specific territories or indications.
The success of REGN3767 and its combination therapies in clinical trials will ultimately determine its commercial impact. However, the patent provides a foundational layer of exclusivity.
Key Takeaways
- Patent 11,058,667 protects methods and compositions for treating NSCLC using antibodies targeting the PD-1/PD-L1 pathway, specifically claiming the antibody REGN3767 and combination therapies.
- The patent includes claims for isolated antibodies binding to PD-1 and PD-L1, pharmaceutical compositions, and methods of treating NSCLC using these antibodies.
- Key combination claims involve REGN3767 with an anti-PD-L1 antibody and a general anti-PD-1 with an anti-PD-L1 antibody.
- The PD-1/PD-L1 pathway is a validated target in NSCLC, with several approved therapies already on the market.
- REGN3767 is Regeneron's investigational anti-PD-1 antibody.
- The patent landscape for PD-1/PD-L1 inhibitors is crowded, with major pharmaceutical companies holding significant IP.
- The patent provides exclusivity for REGN3767 and its specific combination uses, impacting R&D and investment decisions for competitors.
Frequently Asked Questions
-
Will generic versions of REGN3767 be available after this patent expires?
Generic versions would only become available after the expiration of Patent 11,058,667 and any applicable patent term extensions (PTE) or adjustments (PTA). Competitors would also need to avoid infringing on other patents covering REGN3767's manufacturing process or alternative therapeutic uses.
-
Does this patent prevent other companies from developing their own anti-PD-1 or anti-PD-L1 drugs for NSCLC?
No, this patent does not prevent other companies from developing their own anti-PD-1 or anti-PD-L1 drugs, provided those drugs and their methods of use do not infringe on the specific claims of Patent 11,058,667. The patent protects Regeneron's specific antibody (REGN3767) and its claimed combination therapies.
-
What is the distinction between blocking PD-1 and blocking PD-L1?
Blocking PD-1 inhibits the receptor on T cells, while blocking PD-L1 inhibits the ligand, often found on tumor cells. Both mechanisms aim to prevent the inhibitory signal that prevents T cells from attacking cancer. Patent 11,058,667 includes claims for both types of antibodies and their combination.
-
Are there any ongoing clinical trials for REGN3767 in combination therapies for NSCLC?
Regeneron has conducted and continues to conduct clinical trials for REGN3767, often in combination with other agents, including PD-L1 inhibitors and targeted therapies. Specific trial details can be found on clinical trial registries.
-
What is the potential impact of this patent on the pricing of NSCLC treatments?
This patent contributes to the exclusivity period for REGN3767 and its combination therapies, which can influence pricing. During the period of patent protection, the patent holder has the exclusive right to market the patented invention, potentially allowing for premium pricing.
Citations
[1] Regeneron Pharmaceuticals, Inc. (2021). Methods and Compositions for Treating Non-Small Cell Lung Cancer (U.S. Patent No. 11,058,667). United States Patent and Trademark Office.
[2] U.S. Food and Drug Administration. (n.d.). Drug Approval Packages. Retrieved from https://www.fda.gov/drugs/ (Specific drug approval pages are not cited individually here but represent the source for approved indications).
[3] National Cancer Institute. (n.d.). PD-1/PD-L1 Inhibitors. Retrieved from https://www.cancer.gov/about-cancer/treatment/drugs/pd-1-pd-l1-inhibitors
[4] Regeneron Pharmaceuticals, Inc. (2023). Regeneron Pharmaceuticals Reports Third Quarter 2023 Results. Retrieved from https://investor.regeneron.com/news-releases/news-release-details/regeneron-pharmaceuticals-reports-third-quarter-2023-results (Company reports often detail pipeline assets).
[5] Various Patent Databases (e.g., USPTO Patent Full-Text and Image Database, Espacenet, Google Patents). (General reference for competitive patent landscape analysis).
